Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease

Ami Kawamoto; Kento Takenaka; Shuji Hibiya; Kazuo Ohtsuka; Ryuichi Okamoto; Mamoru Watanabe

doi:10.1016/j.cgh.2021.06.036

Serum Leucine-Rich α₂ Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease

Clin Gastroenterol Hepatol. 2022 May;20(5):e1196-e1200. doi: 10.1016/j.cgh.2021.06.036. Epub 2021 Jun 30.

Authors

Ami Kawamoto¹, Kento Takenaka², Shuji Hibiya¹, Kazuo Ohtsuka², Ryuichi Okamoto¹, Mamoru Watanabe³

Affiliations

¹ Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
² Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan; Endoscopic Unit, Tokyo Medical and Dental University Hospital, Tokyo, Japan.
³ TMDU Advanced Research Institute, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: mamoru.gast@tmd.ac.jp.

PMID: 34216822
DOI: 10.1016/j.cgh.2021.06.036

Abstract

Active lesions in the small bowel (SB) have been independently associated with poorer prognoses in patients with Crohn's disease (CD)¹; however, there has been a lack of accurate and convenient screening methods. Past studies have found that serum levels of the glycoprotein leucine-rich α₂ glycoprotein (LRG) correlates with endoscopic activity in ulcerative colitis,^2,3 and this is now available for routine clinical use as a biomarker in patients with inflammatory bowel disease in Japan. LRG has not yet been thoroughly verified in CD, and we investigated whether it can be used as a serum biomarker for detecting SB mucosal activity in patients with CD.

Publication types

Letter

MeSH terms

Biomarkers / analysis
Colitis, Ulcerative* / pathology
Crohn Disease* / diagnosis
Crohn Disease* / pathology
Glycoproteins* / analysis
Humans

Substances

Biomarkers
Glycoproteins